share_log

Cantor Fitzgerald Initiates Coverage On Legend Biotech With Overweight Rating, Announces Price Target of $82

Benzinga ·  Apr 3 07:47

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Target of $82.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment